Leukemia research
Journal
Overview
publication venue for
-
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma.
2007
-
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study..
139.
2024
-
Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation..
127.
2023
-
Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia..
123.
2022
-
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling..
123.
2022
-
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights..
121.
2022
-
De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features..
117.
2022
-
Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy..
106.
2021
-
GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms..
100.
2020
-
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia..
98.
2020
-
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study..
95.
2020
-
Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data..
95.
2020
-
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy..
93.
2020
-
Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer..
82.
2019
-
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib..
79.
2019
-
Widespread use of measurable residual disease in acute myeloid leukemia practice..
67.
2018
-
Disease characteristics and clinical outcomes in patients aged less than 40 with chronic lymphocytic leukemia..
65.
2018
-
Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia..
50.
2016
-
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance..
50.
2016
-
Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS)..
49.
2016
-
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia..
49.
2016
-
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents..
41.
2015
-
Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation..
40.
2015
-
The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML)..
38.
2014
-
Chronic lymphocytic leukaemia cells become both activated and immunosuppressive following interaction with CD3 and CD28 stimulated PBMC..
38.
2014
-
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases..
38.
2013
-
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia..
37.
2013
-
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death..
37.
2013
-
Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors..
37.
2013
-
Sustained disease control in transplant-ineligible patients: the role of continuous therapy..
36 Suppl 1.
2012
-
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis..
37.
2012
-
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?.
36.
2012
-
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo..
36.
2011
-
Treatment of polycythemia vera with imatinib mesylate..
36.
2011
-
Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo..
35.
2010
-
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome..
35.
2010
-
JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy..
35.
2010
-
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib..
34.
2009
-
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition..
34.
2009
-
Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia..
33.
2009
-
Multiple distinct clones may co-exist in different lineages in myelodysplastic syndromes..
33.
2008
-
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia..
31.
2007
-
Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia..
31.
2007
-
Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules..
30.
2006
-
Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan..
29.
2005
-
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase..
27.
2003
-
Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients..
27.
2003
-
Characterization of two novel sublines established from a human megakaryoblastic leukemia cell line transfected with p210(BCR-ABL)..
24.
2000
-
CD40 ligation impedes lymphoblastoid B cell proliferation and S-phase entry..
22.
1998
-
Retroviral transfer of herpes simplex virus-thymidine kinase and beta-galactosidase genes into U937 cells with bicistronic vector..
21.
1997
-
Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells..
21.
1997
-
Age and Hodgkin's disease: the impact of competing risks and possibly salvage therapy on long term survival: an E.C.O.G. study..
17.
1993
-
Differences in the composition and in the efficiency of red cell production of normal and CML erythroid progenitor populations are highlighted by response to human c-kit ligand..
17.
1993
-
Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia..
15.
1991
-
Co-detection of chimeric bcr/abl (target) and beta-actin (control) messenger RNA in individual CFU-GM colonies derived from CML patients using the polymerase chain reaction..
15.
1991
-
A study of multidrug resistance and cell kinetics in a child with near-haploid acute lymphoblastic leukemia..
14.
1990
-
Detection of fos oncogene products by monoclonal antibody FO-120 in lymphoproliferative disorders..
13.
1989
-
Differentiating human leukemia cells express heparanase that degrades heparan sulfate in subendothelial extracellular matrix..
12.
1988
-
Origin of near-haploidy in malignant hematopoietic cells..
12.
1988
-
The predictive value of in-vitro techniques in acute non-lymphocytic leukemia..
11.
1987
-
B-lymphocyte associated differentiation antigen expression by 'non-B, non-T' acute lymphoblastic leukemia..
9.
1985
-
Relationship of Auer rods and chromosome findings to outcome in eighty-nine adults with acute nonlymphoblastic leukemia..
9.
1985
-
Role of interleukin-2 in depressed T-cell mitogenesis after allogeneic marrow transplantation in man..
8.
1984
-
Bone marrow biopsy instead of 'marrow juice' for cell kinetic analysis. Comparison of bone marrow biopsy and aspiration material..
6.
1982
-
Characteristics of bone marrow and blood cells in human leukemia that produce leukemia inhibitory activity (LIA)..
3.
1979
-
Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113..
3.
1979
-
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia..
69.
2018
-
RBC-transfusion guidelines update..
36.
2012
-
What are RBC-transfusion-dependence and -independence?.
35.
2010
-
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia..
30.
2006
-
NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype.
2022
-
Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
2020
-
The third International Congress on Myeloproliferative and Myelodysplastic Syndromes.
2006
-
Immune therapy of chronic myelogenous leukemia.
2005
-
The second international congress on myeloproliferative and myelodysplastic syndromes.
2004
-
The challenge of the 'C' in CML..
38.
2013
-
IMiDs: Not for the CRBN weak..
38.
2013
-
Blood simple: transfusion at home for patients with MDS..
36.
2012
-
FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples..
36.
2011
-
A role for Wnt signaling in adult T-cell leukemia?.
29.
2005
-
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
2014
-
Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia.
2013
-
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.
2018
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)